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Abstract   
 
Since its approval in 1979 cisplatin has become one of the most extensively used 
chemotherapeutics in the clinic and although cell resistance and toxicity hinder its 
efficacy it continues to be a gold standard regimen. Cisplatinǯs side effects primarily 
include nephrotoxicity, gastrointestinal toxicity, neurotoxicity and ototoxicity.  
Cardiotoxicity is generally not defined as a side effect of cisplatin. However, over the past 
decade there has been a surge in the amount of clinical cases reporting a vast array of 
cardio-toxic events occurring during or shortly after cisplatin infusion, these range from 
angina to cardiac ischemia and chronic heart failure. This review intends to discuss the 
clinical cardiac manifestations of cisplatin specifically tachycardia and bradycardia which 
can be lethal and the possible mechanisms of action.  
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1. Introduction 
 
The chemotherapeutic drug cisplatin (cis-diamminedichloroplatinum II) is one of the 
most extensively used drugs in the treatment of cancer. It was the first metal-based drug 
to enter clinical trials in 1972 and first to be used in the clinic in 1979 (Wheate et al., 
2010). Cisplatin is now a gold standard drug in the treatment of testicular cancer in which 
it has a 90% cure rate and is used in the treatment of head and neck, cervical, breast, lung, 
ovarian, gastric, and bladder cancers amongst many more (Wheate et al., 2010, ; Kelland., 
2007; Jamieson et al., 1999; Dasari et al., 2014)   
 
Cisplatin exerts its anti-tumour activity through its alkylating properties. Once it enters 
the cytoplasm of a cell, where the chloride concentration is much lower than that of the 
blood (~20 mM vs ~ 100 mM), it spontaneously and sequentially replaces its chloride 
ligands with water molecules (Wheate et al., 2010). This results in the formation of a 
positively charged bis-aquated platinum complex that is now able to bind to DNA (Dasari 
et al., 2014; Siddik, 2003). Cisplatin predominantly forms intrastrand adducts between 
two adjacent guanines followed by an adjacent guanine and adenine. These adducts cause 
the DNA helix to bend by up to 60% towards the major groove and unwind by 23 ӷ 
therefore inhibiting further DNA replication and transcription and ultimately leading to 
cell death (Wheate et al., 2010; Dasari et al., 2014; Siddik, 2003).  
 
The success of cisplatin in the clinic is hindered by two major limitations: the 
development of cispǯǤWhen cells 
become resistant to cisplatin, the dose of cisplatin administered to the patient is 
increased, which in turn increases the level of its toxic side effects (Siddik, 2003).  
Cisplatin is primarily associated with nephrotoxicity; its dose limiting side effect, 
neurotoxicity and ototoxicity (Wheate et al., 2010; Jamieson et al., 1999). Other common 
side effects include: severe nausea, vomiting, gastrotoxicity and myelosuppression 
(Wheate et al., 2010; Jamieson et al., 1999).  
 
Cardiotoxicity is generally not defined as a common side effect of cisplatin. However, over 
the past decade there has been a surge in the amount of clinical cases reporting a vast 
array of cardio-toxic events occurring during or shortly after cisplatin infusion (Patane, 
2014; El-Awady et al., 2011). These include silent and symptomatic arrhythmias, angina, 
myocarditis, pericarditis, diastolic disturbances, cardiac ischemia, acute myocardial 
infarction, thromboembolic events, and chronic heart failure (CHF). The mechanisms of 
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action of cǯcardiotoxic activity is still unknown and yet to be identified (Patane, 
2014; El-Awady et al., 2011).  
 
It is highly important to note that cisplatin infusion is routinely not administered under 
cardiac monitoring compared to other drugs (such as the anthracyclines) and thus 
cisplatin induced cardiotoxicity particularly those that occur silently may go undetected 
and thus the cardiotoxic effects of cisplatin may well be overlooked and underreported. 
Furthermore, platinum can be found in the plasma of patients twenty years after 
completion of chemotherapy which can lead to long term side effects or toxicity that 
develops years after completion of chemotherapy (Gerl, 2000). Therefore the cardiotoxic 
manifestations of cisplatin is an important issue that needs to be addressed and 
understood.  
 
2. Cisplatin and Arrhythmia 
 
Arrhythmia is ǯ most commonly reported cardiotoxic event occurring in the 
form of tachycardia; supraventricular tachycardia, ventricular arrhythmia, atrial 
fibrillation (AF), bradycardia; sinus bradycardia, bundle branch block and complete 
atrioventricular block with most occurring silently and in some cases being lethal 
(Connobio et al., 1986; Raja et al., 2013). Tachycardia is the most frequent type of 
arrhythmia to occur with cisplatin administration followed by bradycardia.  
 
2.1. Tachycardia 
Tachycardia which can also be referred to as tachyarrhythmia is defined as a heart rate 
that exceeds the normal resting range of 60 Ȃ 100 beats per minute ( for an adult) (Menard 
et al., 1991). In the clinical cases identified in which tachycardia was reported, the 
majority of patients were receiving a combination of intravenous cisplatin and etoposide 
to treat various cancers (Raja et al., 2013; Tassinari et al., 1997; Yavas et al., 2008; Fassio 
et al., 1986).  In some cases, tachycardia (130 Ȃ 230 bpm) was reported to have developed 
within a few minutes of cisplatin infusion in the first cycle of chemotherapy as well as in 
each consecutive cycle, while in others it developed on other days in the first, second or 
sixth cycle (Raja et al., 2013; Tassinari et al., 1997; Yavas et al., 2008; Fassio et al., 1986). 
All patients had no underlying cardiac illness and tachycardia was identified only as a 
result of patientǯs complaints of chest pain, dysponea and palpitations that resulted in ǯ (ECG) and electrolyte serum values evaluated. During the   ǯ       ǡ ǡ
sodium (Na), potassium (K), calcium (Ca), chloride (Cl) and magnesium (Mg) electrolyte 
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concentrations analysed.  Results found that the only significant change in some cases was 
the level of Mg in which it was reduced to 1.2 Ȃ 1.6 mg/dl (normal range of 1.7-2.2 mg/dl.) 
and in a few cases a reduction of both Mg and K levels were described (Tassinari et al., 
1997; Yavas et al., 2008; Fassio et al., 1986). In a report by Tassinari et al, a 68 year old 
patient receiving intravenous 100 mg/m2 cisplatin plus 100 mg/m2 etoposide for the 
treatment of stage III B non-small cell lung cancer (NSCLC) complained of palpitations 
immediately after cisplatin infusion on day one of the first cycle (Tassinari et al., 1997). 
ECG showed rapid AF with a ventricular rate of 160-200 bpm [14].  Blood analysis showed 
no significant changes in serum electrolyte levels (Tassinari et al., 1997). A reduction of ǯcardiac rate to 110 bpm was achieved with intravenous propafenone and 
return to sinus rhythm was achieved after 48 hours (Tassinari et al., 1997). The patient 
refused to continue chemotherapy (Tassinari et al., 1997). In another case, a 66 year old 
patient whom was formerly treated with five courses of 100 mg/m2 cisplatin plus 100 
mg/m2 etoposide also for the treatment of NSCLC complained of palpitations and 
difficulty in breathing after cisplatin infusion on day one of the sixth cycle (Yavas et al., 
2008) ECG showed rapid AF with a ventricular rate of 210 bpm, ǯserum urea, 
K, Ca and Cl levels were normal whereas serum Mg levels were reduced to 1.2 mg/dl 
(Yavas et al., 2008). Return to sinus rhythm was achieved after 48 hours with intravenous 
propafenone plus intravenous magnesium sulphate (Yavas et al., 2008). Bashir et al 
reported a 26 years old patient that developed chronic hypomagnesaemia and 
hypokalaemia following cisplatin treatment, the patient suffered a brief asystolic episode 
for 15-20 sec in which normal sinus rhythm returned spontaneously without any 
intervention (Bashir et al., 2007). In another case reported by Pastorino et al, a 37 year 
old patient receiving combination treatment of 20 mg/m2 cisplatin, 100 mg/m2 etoposide, 
and 30 mg of bleomicin for the treatment of testicular cancer developed AF after cisplatin 
infusion and before etoposide infusion (Pastorino et al., 2016). Low Mg serum levels was 
found to be the only parameter below the normal level despite receiving diluted Mg in 
saline pre-treatment (Pastorino et al., 2016).  
 
2.1.1. Hypomagnesaemia Induced by Cisplatin and its Role in Cardiotoxicity 
Hypomagnesaemia (Mg serum levels less than 1.7 mg/dl) is a well-known complication 
of cisplatin treatment (Lager and Daugaard, 1999; Glaudemans et al., 2010; Daugaard and 
Abildgaard, 1989). Studies have shown that cisplatin induces hypomagnesaemia through 
its nephrotoxic properties by direct injury to the mechanisms of Mg reabsorption 
specifically in in the renal distal convoluted tubule (DCT). The DCT plays an essential role 
in maintaining systemic Mg concentration. It is the final determinant of plasma Mg levels 
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as the more distal nephron segments are impermeable to Mg (Glaudemans et al., 2010; 
Daugaard and Abildgaard, 1989; Bell et al., 1985). The main mechanism in which cisplatin 
causes injury is still unknown but believed to include disturbances at the melastatin 
receptor, the voltage gated K channel and epidermal growth factor protein (Daugaard and 
Abildgaard, 1989; Bell et al., 1985). The reported incidence of patients developing 
hypomagnesaemia at some point during cisplatin treatment varies between 40-100% 
dependant on the course schedule and dosage (Lager and Daugaard, 1999]. Buckley et al 
reported that the incidence of hypomagnesaemia in patients receiving 50 mg/m2 of 
cisplatin was found to increase from 41% after the first course of treatment to 100% in 
patients receiving six courses of chemotherapy (Buckley et al., 1984). Bell et al studied 
patients receiving different regimens of cisplatin and found that all patients developed 
hypomagnesaemia after four courses of chemotherapy irrespective of the dosage taken 
(50-100 mg/m2) (Bell et al., 1985).  
 
The clinical manifestations of Mg deficiency include neuromuscular abnormalities such 
as tremor and ataxia, psychiatric disturbances such as confusion and hallucinations, and 
cardiotoxicity such as ECG changes (including changes in QT intervals) and arrhythmias 
(Lager and Daugaard, 1999; Buckley et al., 1984; Afus and Agus, 2001; Douban et al., 
1996). Reports of cardiotoxicity developing as a result of hypomagnesemia are not as 
common, however there is sufficient in vivo evidence to suggest a correlation. In a study 
conducted by Fiset et al, the correlation between hypomagnesaemia and cardiac death 
was studied in rats (Fiset et al., 1996). Results found that 80% of the hypomagnesaemia 
rats suffered -episodes of bradycardia and tachycardia compared to the control group in 
which 0% showed any cardiac adversity (Fiset et al., 1996). As well as this, 36% of rats in 
the hypomagneseamic group suffered sudden unexpected asystolic death compared to 
0% in the control group (Fiset et al., 1996). In a study by Yusuf et al, tachycardia was the 
prime manifestation of Mg depletion in experimental animals followed by bradycardia 
(Afus et al., 2001). In a clinical study by Oladapo et al, the occurrence of arrhythmia in 
relation to Mg serum concentrations in CHF patients was studied (Douban et al., 1996). 
Results showed that in the CHF arm patients that suffered arrhythmias had a significantly 
lower serum Mg concentration compared to the CHF arm that did not suffer a form of 
arrhythmia (Douban et al., 1996).  Furthermore, there are a number of clinical cases 
which report the association between magnesium deficiency and sudden cardiac death in 
humans (Efstratiadis et al., 2006). However in some cases there has been no clear cause 
and direct relation as there may have been other potential confounders (Efstratiadis et 
al., 2006).  
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There are only a few clinical cases published that link cisplatin induced hypomagnesemia 
with cardiac dysrhythmias as discussed above. However, it is important to note that the 
exact time taken for the development of hypomagnesemia was not investigated in any of 
the reported clinical cases. Furthermore, there is no   ǯs Mg serum 
levels were within normal range before initiation of cisplatin therapy.  Therefore it is 
difficult to suggest that hypomagnesemia is the sole reason to tachycardia, especially in 
cases in which tachycardia developed within minutes of cisplatin infusion as 
hypomagnesemia can take longer to develop.  
 
Interestingly, in other cases, arrhythmia has been reported to develop with cisplatin 
infusion independent of serum electrolyte levels suggesting that another mechanism of 
action is in play (Yavas et al., 2008). In a study by Yavas et al, patients receiving 20-100 
mg/m2 of cisplatin plus etoposide for treatment of various cancers underwent intensive 
cardiac monitoring. Results showed that 67% of patients had asymptomatic 
supraventricular or ventricular arrhythmia during the infusion period with no changes to 
blood pressure or serum electrolyte values including that of Mg (Yavas et al., 2008). The 
only significant change found was an increase in the length of QT dispersion that indicated 
a delay in repolarization (Yavas et al., 2008). It was suggested that cisplatin may have 
induced arrhythmias in these cases by affecting cardiac sodium channels (Yavas et al., 
2008).  However, these two changes can occur independently; it is possible for QT 
lengthening to occur without increased dispersion and vice versa. 
 
Evidently there is conflicting results as to whether hypomagnesemia alone is a cause of 
tachycardia.  To answer this question it is important to investigate the correlation 
between the development of hypomagnesemia and occurrence of rhythm disturbances. 
Furthermore, the effect of Mg supplementation before or after cisplatin treatment on the 
occurrence of rhythm disturbances may also provide some critical answers.  Currently 
there is no published data on this topic. 
 
 2.2. Bradycardia 
At the other end of the arrhythmic spectrum, cisplatin has also been reported to induce 
bradycardia (slow heart rate of below 60 bpm) (Kucharz et al., 2016).  In the clinical cases 
identified bradycardia was reported to occur during or shortly after cisplatin infusion 
with no disturbances detected in pǯs or in blood 
pressure or other physical examinations. Furthermore, in the majority of cases reported 
bradycardia resolved on its own without any treatment. In a report by Kucharz et al, a 58 
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year old patient was found to suffer from recurring bradycardia after cisplatin infusion in 
each of the three cycles of chemotherapy (Kucharz et al., 2016). The patient was receiving 
25 mg/m2 cisplatin and 100 mg/m2 etoposide and following the initial 48 h of the first 
cycle of chemotherapy exhibited resting dyspnea, chest discomfort and was found to be 
suffering from severe symptomatic bradycardia (Kucharz et al., 2016). The patient was 
found to have a heart rate reduction to 40 bpm and was treated with intravenous atropine 
which aided in raising ǯate to ~ 70 bpm (Kucharz et al., 2016). These 
episodes of bradycardia (~ 40 bpm) were observed again during the second and third 
treatment cycles (Kucharz et al., 2016). The patient was found to have no significant 
changes in serum electrolyte concentrations (Kucharz et al., 2016). In another case 
reported by Darling, a 15 year old patient receiving salvage combination treatment of 
cisplatin, bleomycin and methotrexate for the treatment of bony and distant lymph nodal 
metastases was incidentally found to have asymptomatic sinus bradycardia (heart rate of 
38 bpm) post cisplatin hydration on the first day of chemotherapy (Darling, 2015). The 
patient exhibited no nausea or vomiting and physical examinations including blood 
pressure were within normal limits as were serum electrolyte levels (Darling, 2015). The ǯed to normal after six hours without any intervention (Darling, 
2015). On the following second day of treatment, the patient received cisplatin infusion 
at a slower cautious rate under intensive cardiac monitoring (Darling, 2015). The patient 
was found to exhibit asymptomatic bradycardia again after 30 minutes of cisplatin 
treatment with heart rate returning to normal after 24 h (Darling, 2015). The patient 
continued to suffer from asymptomatic bradycardia during and after cisplatin infusion on 
the following three days of chemotherapy (Darling, 2015).  Cabuk et al also reported a 
patient that exhibited recurrent asymptomatic bradycardia (40 bpm) during cisplatin 
infusion (Cabuk et al., 2013)Ǥǯerum electrolyte levels 
were also within normal limits (Cabuk et al., 2013). In two other different cases reported 
by Schlaffer et al and Altundag et al, asymptomatic bradycardia was observed in patients 
receivǯ
serum electrolyte concentrations (Schlaeffer et al., 1983; Altundag and Kars, 2001).  
 
The mechanism of action in which cisplatin induces bradycardia has still not been 
identified. However it has been hypothesised to occur as a result of disposition of cisplatin 
at the SA node which may cause disruption in the electrical conduction system of the heart 
(Kucharz et al., 2016; Darling, 2015; Cabuk et al., 2013).  
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2.2.1. Cisplatin and the SA Node 
There is no published data in which the direct effect of cisplatin on the SA node has been 
studied. However, the inotropic effect of cisplatin on heart atria has been investigated 
(Oun et al., 2014). In this ex vivo electrophysiological study, both rat right and left atria 
were incubated with cisplatin and changes to the rate and force of atria contraction were 
recorded at specific intervals over a two hour period (Oun et al., 2014). Results showed 
that by the end of the two hours, cisplatin had significantly reduced the ǯ
and force of contraction by 69% and 54% respectively (Oun et al., 2014). However, in the 
left atria, cisplatin induced no significant changes in the rate of contraction and had 
decreased the force of contraction by 55% (Oun et al., 2014). Furthermore, when cisplatin 
was encapsulated within a drug delivery system, cucurbit[7]uril, the cardiotoxic effect of 
cisplatin on the right atria was significantly reduced by 58% (Oun et al., 2014). Therefore, ǯǡ
the authors hypothesised that cisplatin may have induced these bradycardia events by 
acting on the SA node (Oun et al., 2014). However these results alone are not sufficient to 
confirm that cisplatin does interfere with the SA node and that this is the mode of action ǯǤ	ǡ
be of interest to study the effect of cisplatin on the action of the spontaneous diastolic 
depolarization phase of the sinoatrial cells.  
 
3. Conclusion 
There is a number of clinical and lab-based data that strongly portray cisplatin as a 
cardiotoxic agent. Whether cisplatin induces its cardiotoxic activity directly on the heart 
or indirectly through its nephrotoxic properties is a matter that still needs to be identified. 
The significance of electrolyte imbalance induced by cisplatin, particularly that of Mg is 
regarded as an important factor to its cardiotoxic activity. However, the difficulty in 
measuring intracellular concentrations of Mg as well as the fact that serum Mg levels 
represents only <1% of total body Mg storage puts the theory to debate.  Furthermore, it 
is possible that the intensive saline hydration and the use of mannitol during cisplatin 
treatment (to decrease the risk of nephrotoxicity) may play a part in decreasing Mg 
proximal reabsorption.   
 
Due to the severity of its asymptomatic arrhythmic potential it is important that cisplatin 
infusion is administered under cardiac monitoring especially with patients suffering with 
cardiac problems or whom have a history of cardiac complications.  
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